molnupiravir 46
It is the name of an experimental product used as a prodrug against influenza and in some cases against Covid. It is a nucleoside derived from N4-hydroxycitidine that is used as an antiviral that induces errors in the spread of the virus by tricking its RNA and decreasing replication. It was initially developed at Emory University, Atlanta, United States. It is currently commercially developed by Merck Co Laboratories (MSD). According to studies, efficiency has been detected against several types of Coronavirus (such as SARS, MERS and SARS-CoV-2).